Josh Davis @gurujosh - Bluesky Profile

Congratulations to the RSI trial team #CCRdownunder

10.12.2025 00:34 — 👍 4 🔁 2 💬 1 📌 0

Safety, tolerability, and pharmacokinetics of a 2 g subcutaneous dose of ceftriaxone as an alternative to intravenous delivery ABSTRACTSubcutaneous delivery of antibiotics is a practical alternative to intravenous administration. Ceftriaxone is commonly used for a variety of infections with limited data on the safety and pharmacokinetics of a 2 g subcutaneous dose. This was a prospective, self-controlled cross-over study in 20 stable inpatients receiving ceftriaxone for their infection. Following an intravenous dose, participants received a single dose of 2 g subcutaneous ceftriaxone, in 50 mL normal saline via gravity feed. Capillary dried blood spots were collected at baseline, 1, 2, 4, 8, and 24 hours following the subcutaneous and intravenous doses. Pain scores and infusion site reactions (edema/erythema) were assessed. Ceftriaxone concentrations were measured using a validated liquid chromatography-tandem mass spectrometry assay. A population pharmacokinetic model was developed using nonlinear mixed-effects modeling. The highest median (interquartile range) pain score within the first 2 hours following infusion of a subcutaneous dose of 2 g ceftriaxone was 2.5 (1–4). All participants were pain-free 4 hours after the infusion. The estimated bioavailability was 95.7% (95% bootstrap interval 90.3–99.5). Compared with intravenous, subcutaneous administration resulted in lower peak and comparable trough concentrations. The probability of target attainment for free drug concentrations was similar to intravenous administration for most common infections in hospitalized patients. Subcutaneous administration of 2 g ceftriaxone is well tolerated and has a comparable pharmacokinetic profile relative to intravenous dosing in non-critically ill patients with severe infections.IMPORTANCEThis prospective, self-controlled cross-over design study demonstrates that subcutaneous administration of 2 g ceftriaxone appears safe and well tolerated with a comparable pharmacokinetic profile relative to intravenous dosing in non-critically ill patients with severe infections.CLINICAL TRIALSThis study was registered at ACTRN12624000692538.

Study of 20 pts showed 2g SC ceftriaxone had 95.7% bioavailability, lower peak but similar trough vs IV; pain score max 2.5, pain-free by 4h; safe & well tolerated.💉🦠

#idsky

01.12.2025 10:30 — 👍 1 🔁 1 💬 0 📌 0

The CLARITY initiative: Clinical Literature Appraisal and Research education in InfecTious diseases and microbiologY Over the past two decades, the generation and application of clinical evidence in the fields of clinical infectious diseases and microbiology have entered a new era: one in which clinical guidelines a...

📣 We're thrilled to be part of #CLARITY, an initiative led by Josh Davis @gurujosh.bsky.social & @steventong.bsky.social for physicians, pharmacists & #clinmicro specialists passionate about #clinicalresearch & #evidence appraisal.
Join us! 🌱

#IDSky #MedSky #MedEd

www.cmi-comms.org/article/S295...

01.12.2025 07:20 — 👍 10 🔁 3 💬 1 📌 1

Parliament just passed into law the independent Australian Centre for Disease Control 🎉
The interim CDC will now move from under the Department of Health, Ageing, and Disability to an independent entity as of 1 Jan 2026!

#auspol #idepi #episky #medsky #idsky

06.11.2025 07:21 — 👍 9 🔁 2 💬 0 📌 0

#IDSky #PedsID

27.10.2025 20:27 — 👍 8 🔁 2 💬 0 📌 0

Great to speak with @thelancetinfdis.bsky.social together with @gurujosh.bsky.social about adaptive platform trials in infectious diseases!

23.10.2025 11:38 — 👍 13 🔁 8 💬 1 📌 0

Sorry dud link. See reply

23.10.2025 04:39 — 👍 1 🔁 0 💬 0 📌 0

How long do labs need to incubate #PJI specimens for? Clinicians and some guidelines want long (10-14 days) BUT with modern media and processes, this is probably not needed. See our new paper here sciencedirect.com/science/articl…
@#IDSky

21.10.2025 20:38 — 👍 9 🔁 0 💬 2 📌 0

Big congrats Amy and Richie!

20.09.2025 09:58 — 👍 1 🔁 0 💬 0 📌 0

Let me know if your fellows have any questions for the authors!

04.07.2025 02:03 — 👍 3 🔁 0 💬 0 📌 0

Thrilled to share our new research led by Jane Davies @menziesresearch.bsky.social on First Nations people in the NT living with chronic hepatitis B. An important study that could inform better care:

doi.org/10.1186/s128...

#idsky #MedSky #HepSky #LiverSky

02.07.2025 01:31 — 👍 6 🔁 4 💬 2 📌 0

Making sense of hierarchical composite endpoints in randomized clinical trials – a primer for infectious disease clinicians and researchers Hierarchical composite endpoints (HCEs) are increasingly being used in infectious diseases research. In this review aimed at educating the clinical reader,

Our review on hierarchical composite endpoints (HCEs) has just been published in @cidjournal.bsky.social:
doi.org/10.1093/cid/...

We provide a conceptual overview of HCEs, explain the different associated target parameters and analytic methods.

@steventong.bsky.social @gurujosh.bsky.social

16.06.2025 01:52 — 👍 11 🔁 4 💬 1 📌 0

Communicable E28: Late-breaker trials at ESCMID Global: Should they change your practice? - part 2 Editors of CMI Comms, Josh Davis, Erin McCreary and Emily McDonald...

🎙️ Just published a new #Communicable episode: Communicable E28: Late-breaker trials at ESCMID Global: Should they change ...

Hosted by Josh Davis @gurujosh.bsky.social
Erin McCreary @erinmccreary.bsky.social
Emily McDonald @dremilymcd.bsky.social

Listen here:

#IDSky #Clinmicro #MedSky

01.06.2025 22:01 — 👍 13 🔁 8 💬 0 📌 1

Communicable E27: Late-breaker trials at ESCMID Global: Should they change your practice? - part 1 This episode of Communicable takes on a special format where editors of...

🎙️ Just published a new #Communicable episode: Communicable E27: Late-breaker trials...

Hosted by Marc Bonten @marcbonten.bsky.social
Josh Davis @gurujosh.bsky.social
Erin McCreary @erinmccreary.bsky.social
Emily McDonald @dremilymcd.bsky.social

Listen here:

#IDSky #Clinmicro #MedSky

18.05.2025 22:01 — 👍 12 🔁 8 💬 0 📌 1

⏰ Tune in Monday for the latest #Communicable and hear the complete discussion w/ our editors on some of the late breaker trials at #ESCMIDGlobal '25, part 1! 🎙️

@gurujosh.bsky.social @dremilymcd.bsky.social @erinmccreary.bsky.social @marcbonten.bsky.social @escmid.bsky.social

#IDSky #clinmicro

16.05.2025 06:30 — 👍 12 🔁 4 💬 1 📌 2

Has been great interacting with >850 orthopods and ID doctors from >50 countries at the www.icmortho.com meeting. Lots of interest in the #ROADMAPtrial!

10.05.2025 14:54 — 👍 5 🔁 0 💬 0 📌 0

SNAP Out of It: Rethinking Antistaphylococcal Penicillins for S. Aureus Bacteremia – The SNAP Trial PSSA/MSSA Results Podcast Episode · Breakpoints · 05/04/2025 · 1h 11m

such a joy to discuss PSSA/MSSA domains of SNAP. incredible work led by @gurujosh.bsky.social @steventong.bsky.social conversation w/ the fabulous @angelahuttner.bsky.social

joint effort @escmid.bsky.social Communicable & @sidpharm.bsky.social Breakpoints podcast

podcasts.apple.com/us/podcast/s...

05.05.2025 16:08 — 👍 20 🔁 8 💬 1 📌 0

The Frank-Starling law of Selective Digestive Decontamination More than hundred years ago a series of experiments demonstrated that increased strechting of heart muscles (through higher venous return) increased stroke volume (cardiac output). But not endlessly, ...

Debated for 40 years: Selective Decontamination of the Digestive tract in ICU patients (antibiotics to prevent ICU-acquired infections). My editorial to Josh Davis @gurujosh.bsky.social and Allen Cheng @peripatetical.bsky.social pro-con in @cmicomms.bsky.social.

www.cmi-comms.com/article/S295...

09.05.2025 06:01 — 👍 12 🔁 4 💬 0 📌 1

Selective Digestive Tract Decontamination in the Intensive Care Unit: Life Saver or Recipe for Disaster? “Selective digestive tract decontamination” (SDD) refers to the use of antibiotics to decrease bacterial load in the gut with the intention of reducing the risk of pneumonia (from microaspiration) and...

And thank you to @gurujosh.bsky.social & A Cheng for their pro-con piece on selective digestive decontamination (w/ #antibiotics) in #ICU patients

Whose side do you take?

#IDSky #Clinmicro #MedSky #PharmSky #AMR #ICUSky #Criticalcaresky @marcbonten.bsky.social

www.cmi-comms.com/article/S295...

09.05.2025 17:00 — 👍 5 🔁 2 💬 0 📌 0

SNAP Trial Helps Resolve Long-Running Controversies Over Management of Staph Bacteremia For those who do hospital-based patient care, the significance of Staphylococcus aureus bacteremia (SAB) cannot be overstated. It’s one of the most frequent reasons for infectious disease consultation...

The SNAP trial may finally resolve some of the longest-running debates in SAB management (cefazolin vs semi-synthetic PCN? Is PCN really active vs PSSA?).
Huge congrats to Drs. Joshua Davis, Steven Tong, & the global team who made this ambitious trial happen. #IDSky blogs.jwatch.org/hiv-id-obser...

18.04.2025 20:35 — 👍 69 🔁 20 💬 3 📌 1

Yes. I think it’s mostly because X has mostly (but not completely) died for ID stuff and Bluesky is still not working as well as Twitter did at its peak

15.04.2025 17:56 — 👍 7 🔁 0 💬 1 📌 0

$5 million boost for world-first trial tackling strep infections in both children and adults A major new clinical trial, the Streptococcal Adaptive Platform (STRAP), has received $5 million in funding from the Australian Government’s Medical Research Future Fund (MRFF) to improve treatment for life-threatening streptococcal infections across all age groups. Lead by researchers and clinicians from the Doherty Institute, Murdoch Children's Research Institute (MCRI), and other national and international partners.

SNAP is extending from S aureus to invasive streptococcal infections!

A new platform trial for iGAS and iSDSE

@gurujosh.bsky.social @joshosowicki.bsky.social @drmichaelmarks.bsky.social

www.doherty.edu.au/news-events/...

15.04.2025 06:25 — 👍 42 🔁 14 💬 1 📌 3

Taking a break from talking about #SNAPtrial to work on a new collaboration
#IDSky #ESCMIDglobal
@steventong.bsky.social

14.04.2025 15:19 — 👍 19 🔁 0 💬 2 📌 0

Yep me and most people I know will think twice (or thrice) before going to US conferences for the next few years

14.04.2025 13:19 — 👍 1 🔁 0 💬 0 📌 0

Alpha toxin at high concentration punches holes in host cells. At lower concentrations it binds to ADAM10 (present in many cell types) and thus indirectly causes cell death

14.04.2025 13:06 — 👍 1 🔁 0 💬 0 📌 0

Julianne Wardenberg on S.aureus pathogenesis at #ESCMIDglobal. Alpha toxin is a key virulence factor. First described by Frank Macfarlane Burnet in 1929!
#IDSky

14.04.2025 13:03 — 👍 6 🔁 0 💬 1 📌 0

We had not planned but can put this on the to do list!

14.04.2025 05:55 — 👍 2 🔁 0 💬 1 📌 0

I had not seen these data before. Is it published?

14.04.2025 05:55 — 👍 0 🔁 0 💬 1 📌 0

And in the big SNAP trial run 🏃‍♀️ for MSSA... it's cefazolin crossing the line ahead of (flu)cloxacillin 🏅

Cefazolin manufacturers are gonna have to really step up after this (still on shortage restrictions in 🇬🇧 😢)

RIP fluclox 🪦

@gurujosh.bsky.social gave an excellent talk 🥁

#ESCMIDGlobal

12.04.2025 14:58 — 👍 14 🔁 1 💬 1 📌 0

The most anticipated RCT in ID
🔥SNAP RCT🔥The largest RCT 2 date in SA bactermia
N:1341
Cefazolin Vs ASPs ((flu)cloxacillin) for MSSA bacteremia
Cefazolin is non-inferior (90d mortality)& less AKI than ASPs
A practice-changer RCT that must change the guidelines
#ESCMIDGlobal #IDSky

12.04.2025 15:09 — 👍 71 🔁 21 💬 2 📌 3

Josh Davis

Latest posts by gurujosh.bsky.social on Bluesky

@gurujosh is following 20 prominent accounts